Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8444450 | European Journal of Cancer | 2013 | 6 Pages |
Abstract
While ALK translocations are not present in oesophageal cancer, ALK amplifications are common events with comparable rates in SCC and AC. Since ALK amplified breast cancer cells were shown to respond to ALK inhibitors, ALK amplified oesophageal cancers might be considered as possible candidates for therapies targeting ALK.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sebastian F. Schoppmann, Berthold Streubel, Peter Birner,